🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Mexico
Clinical trial register · Mexico

Studies with a Mexican investigative site

Every study on the ClinicalTrials.gov registry that lists a site in Mexico and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1579 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:45 UTC
1579
Studies in scope
all four open statuses
711
Recruiting now
open to new participants
247
Lead sponsors
across recruiting studies
Top sites
Mexico City 586 Monterrey 370 Guadalajara 342 Chihuahua City 175 Mérida 135
Narrow the register
Recruitment status
Phase
Lead sponsor
National Cancer Institute (NCI)116 AstraZeneca66 Merck Sharp & Dohme LLC63 Hoffmann-La Roche61 Eli Lilly and Company56
Site location
Mexico City586 Monterrey370 Guadalajara342 Chihuahua City175 Mérida135
All 197 locations
Target enrolment
to

Trials in this register

1579 of 1579 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Mexico
Start
Recruiting
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
NCT05958342Trauma, Hemorrhage
DrugsCalcium Gluconate·Vasopressin
Jason Sperry
Phase 2
1,050
2024-06-30
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Guadalajara, Mexico City, Veracruz
2024-06-29
Active, closed
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NCT06331312Polymyalgia Rheumatica
DrugSecukinumab
Novartis Pharmaceuticals
Phase 3
162
Guadalajara
2024-06-28
Active, closed
A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
NCT06455098Atrial Fibrillation
Biosense Webster, Inc.
Not applicable
354
2024-06-28
Active, closed
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228Hidradenitis Suppurativa
DrugLutikizumab
AbbVie
Phase 3
1,400
Guadalajara, Mexico City, Monterrey, Veracruz
2024-06-27
Active, closed
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)
NCT06498661Cervical Carcinoma, Human Papillomavirus Infection
National Cancer Institute (NCI)
Not applicable
750
2024-06-26
Recruiting
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485Rectal Cancer
DrugsLeucovorin·Capecitabine·Oxaliplatin
Canadian Cancer Trials Group
Phase 3
250
2024-06-26
Active, closed
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
10,000
Aguascalientes, Torreón, Guadalajara, México, Tlalpan, Cuauhtémoc, Monterrey, Culiacán
2024-06-25
Recruiting
Evaluation of Cognitive Improvement After Bariatric Surgery Using a Virtual Reality Program and the Neuropsi Neuropsychological Battery
NCT07229924Obesity (Disorder), Obesity and Obesity-related Medical Conditions
Hospital General de México Dr. Eduardo Liceaga
Not applicable
42
Mexico City
2024-06-25
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374Triple-Negative Breast Cancer
DrugsSacituzumab tirumotecan·Capecitabine·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,530
Benito Juárez, Mexico City, San Pedro Garza García
2024-06-24
Recruiting
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
NCT06203600Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8
DrugsRamucirumab·Nivolumab·Paclitaxel
National Cancer Institute (NCI)
Phase 2/3
224
2024-06-24
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Culiacán, D.F, Guadalajara, Mexico City, México
2024-06-20
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone
Celgene
Phase 3
850
Mexico City, Morelia, Monterrey, Oaxaca City, Puebla City
2024-06-19
Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
DrugsEmavusertib·Epoetin Alfa·Eprex·Enasidenib
National Cancer Institute (NCI)
Phase 2
2,000
2024-06-18
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288Heart Failure
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
6,712
Aguascalientes, Culiacán, Distrito Federal, Guadalajara, Irapuato, México, Monterrey, Tlalnepantla
2024-06-17
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754Non-small Cell Lung Cancer (NSCLC)
DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
550
Guadalajara, Mexico City, Monterrey, Oaxaca City
2024-06-11
Active, closed
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT06472076Lung Cancer, Non-Small Cell
DrugsBelrestotug·Dostarlimab·Pembrolizumab
GlaxoSmithKline
Phase 3
88
Guadajalara, La Paz BCS, Mexico City, San Luis Potosí City
2024-06-10
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
DrugsSacituzumab tirumotecan·Keytruda·Nab-paclitaxel·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
851
2024-06-10
Active, closed
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06082167Head and Neck Squamous Cell Carcinoma
DrugsZanzalintinib·Keytruda·Pembrolizumab
Exelixis
Phase 2/3
600
Guadalajara, San Juan del Río
2024-06-07
Active, closed
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249Systemic Lupus Erythematosus
DrugBelimumab
GlaxoSmithKline
Phase 4
303
Cuauhtémoc, DF, Guadalajara Jalisco, León, Mexico City, Mérida, Monterrey Nuevo LeOn, San Luis Potosí City
2024-06-06
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 3
563
Mexico City
2024-06-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,200
León, Tlajomulco de Zúñiga, Mexico City, Cuernavaca, Monterrey, San Pedro Garza García, Oaxaca City, Mérida
2024-06-05
Recruiting
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314Advanced Melanoma
DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab
Immunocore Ltd
Phase 3
680
Guadalajara, Mexico City
2024-06-05
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277Obesity, Weight Gain
DrugTirzepatide
Eli Lilly and Company
Phase 3
300
Aguascalientes, Guadalajara, Monterrey, Puebla City
2024-06-03
Recruiting
Multimodal Image Analysis and Guidance of Neuromodulation for Trauma-Related Symptoms
NCT06449326Posttraumatic Stress Disorder
University of New Mexico
Not applicable
64
2024-06-01
Active, closed
Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).
NCT06253923Traumatic Brain Injury
SHINKEI Therapeutics, Inc
Phase 2
45
2024-06-01
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
89bio, Inc.
Phase 3
762
Chihuahua City, Cuautitlán Izcalli, Cuernavaca, Jalisco, Mexico City, Mérida, Monterrey
2024-05-24
Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT06345729Non-small Cell Lung Cancer
DrugsCalderasib·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
600
Mexico City, Monterrey, Oaxaca City
2024-05-24
Recruiting
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
NCT05931276End-Stage Kidney Disease, End-Stage Renal Disease
DrugsMetoprolol Succinate·Carvedilol
VA Office of Research and Development
Phase 3
2,540
2024-05-22
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
550
León, Guadalajara, Mexico City, Morelia, Mérida, México
2024-05-21
Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665Asthma
AstraZeneca
Phase 3
440
Chihuahua City, Guadalajara, Monterrey
2024-05-20
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Aguascalientes, Cuernavaca, Monterrey, Veracruz
2024-05-20
Recruiting
Cervical Boost by Ablative Stereotactic Radiotherapy (SABR) vs Brachytherapy in Patients With Cervical Carcinoma
NCT06560697Uterine Cervical Neoplasm
National Institute of Cancerología
Not applicable
84
Mexico City
2024-05-15
Active, closed
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
NCT06079359Hypophosphatasia
DrugALXN1850
Alexion Pharmaceuticals, Inc.
Phase 3
30
Chihuahua City
2024-05-14
Active, closed
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966Focal Epilepsy
DrugBHV-7000
Biohaven Therapeutics Ltd.
Phase 2/3
390
Mexico City, Monterrey, Obispado, Sinaloa, Tlalnepantla, Veracruz
2024-05-13
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 3
1,541
Monterrey, Aguascalientes, Durango, Veracruz
2024-05-08
Recruiting
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
NCT06126276Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm
DrugsNeratinib·Palbociclib
National Cancer Institute (NCI)
Phase 2
70
2024-05-07
Active, closed
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
DrugNerandomilast
Boehringer Ingelheim
Phase 3
1,666
Chihuahua City, Coyoacán, León, Mexico City, Monterrey, Oaxaca City
2024-05-06
Active, closed
Effect of an Intervention With Apple Cider Vinegar on Glycemic Variability and Lipid Profile in Patients With Type 2 Diabetes Mellitus
NCT07493707Type 2 Diabetes Mellitus 2
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Not applicable
38
Mexico City
2024-05-06
Active, closed
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311Gastroesophageal Cancer
DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
450
Guadalajara, Mexico City, Monterrey, Oaxaca City, San Luis Potosí City
2024-05-03
Recruiting
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
NCT06361537Acute Hereditary Angio Edema
Octapharma
Phase 3
124
Mexico City, México
2024-04-30
Active, closed
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
DrugRetatrutide
Eli Lilly and Company
Phase 3
10,000
Actopan, Aguascalientes, Ciudad Madero, Cuauhtémoc, Ciudad de México, Cuernavaca, Durango, Guadalajara, León
2024-04-30
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
DrugLebrikizumab
Eli Lilly and Company
Phase 3
510
Aguascalientes, Chihuahua City, Guadalajara Jalsico, Nuevo León, Oaxaca City
2024-04-29
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961End Stage Kidney Disease
DrugCSL300
CSL Behring
Phase 2/3
3,110
Mexico City, Monterrey
2024-04-27
By invitation
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
NCT06194799Alzheimer's Disease Psychosis
DrugACP-204
ACADIA Pharmaceuticals Inc.
Phase 3
752
Monterrey, Culiacán, Coahuila, Estado de México, San Luis Potosí City
2024-04-23
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296Ganglioneuroblastoma, Nodular, Neuroblastoma
DrugsDinutuximab·Isotretinoin·CDDP·Doxorubicin
National Cancer Institute (NCI)
Phase 3
478
2024-04-19
Recruiting
MDMA for Co-occurring PTSD and OUD After Childbirth
NCT05219175Stress Disorders, Post-Traumatic, Opioid Use Disorder
University of New Mexico
Phase 2
15
2024-04-16
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Guadalajara, Benito Juárez, Mexico City, Veracruz. Mexico City
2024-04-16
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176Breast Neoplasms
DrugsLiposomal doxorubicin·Sacituzumab tirumotecan·Nab-paclitaxel·Capecitabine
Merck Sharp & Dohme LLC
Phase 3
1,200
Guadalajara, Mexico City, Monterrey, San Pedro Garza García
2024-04-14
Active, closed
A Study of Barzolvolimab in Patients With Prurigo Nodularis
NCT06366750Prurigo Nodularis
DrugBarzolvolimab
Celldex Therapeutics
Phase 2
140
2024-04-12
Recruiting
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652Heart Failure and Impaired Kidney Function
AstraZeneca
Phase 3
3,850
Aguascalientes, Chihuahua City, Cuauhtémoc, Culiacán, Guadalajara, Mazatlán, Metepec, Mexico City
2024-04-12
Active, closed
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
NCT06295367Malignant Solid Neoplasm
ECOG-ACRIN Cancer Research Group
Not applicable
760
2024-04-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064Recurrent or Metastatic Solid Tumors
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 1/2
680
Mérida, México
2024-04-10
Active, closed
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
NCT06245408Sjögren's Syndrome (SS)
DrugDazodalibep
Amgen
Phase 3
434
Parques de San Felipe, Torreón Centro, Mexicali, Americana, Mexico City, San Miguel Chapultepec, Centro, México
2024-04-08
Recruiting
BostonGene and Exigent Genomic INsight Study
NCT06272864Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
BostonGene
Observational
400
2024-04-08
By invitation
Use of a Mobile Application by Parents to Prevent Obesity in Their Children Apply for Your Health
NCT07376252Obesity, Overweight
Hospital Infantil de Mexico Federico Gomez
Not applicable
743
Mexico City
2024-04-08
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137Non Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
780
Guadalajara, Monterrey, Oaxaca City, Chihuahua City
2024-04-03
Active, closed
Mobile Health for Adherence in Breast Cancer Patients
NCT06112613Breast Carcinoma
ECOG-ACRIN Cancer Research Group
Not applicable
390
2024-04-02
Active, closed
Effect of Agave Inulin Supplementation on Metabolic Profile and Intestinal Abundance of Bifidobacterium and Lactobacillaceae in Adults With Type 2 Diabetes Mellitus
NCT07696247Type 2 Diabetes, Gut Microbiota, Insulin Resistance, Metabolic Syndrome
Universidad Autonoma de Queretaro
Not applicable
43
Querétaro City
2024-04-01
Recruiting
Particulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection
NCT06268704Sacroiliac Joint Dysfunction, Sacro-Iliac Spondylosis
DrugsOzurdex·Lidocaine HCl·Depo-Medrol·Solu-Medrol
University of New Mexico
Phase 4
230
2024-03-27
Active, closed
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
NCT06333808HIV-1-infection
DrugsBictegravir·B/F/TAF·Lenacapavir
Gilead Sciences
Phase 3
577
Mexico City, Mérida
2024-03-25
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06257875Ulcerative Colitis
DrugsLutikizumab·Humira·Adalimumab
AbbVie
Phase 2
156
2024-03-23
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588Neoplasms, Head and Neck
DrugDostarlimab
GlaxoSmithKline
Phase 3
864
Guadajalara, Guadalajara, Mexico City, Monterrey, Oaxaca City
2024-03-21
By invitation
Study to Collect Data for Neonatal Abstinence Syndrome (NAS) and Evaluate the Automated Data Collection Process
NCT06303986Neonatal Abstinence Syndrome
Rekovar Inc.
Observational
100
2024-03-18
Recruiting
Effect of Repetitive TMS on Executive Function in Alcohol Use Disorder
NCT05997212Alcohol Use Disorder
Universidad Nacional Autonoma de Mexico
Not applicable
44
Querétaro City
2024-03-16
Recruiting
Neuroprotective Effect of (Nano PSO), in Patients Who Used to Consume Psychoactive Substances
NCT06550167Addiction;Drug(S);LSD, Neuroprotective
Distribuidora Biolife SA de CV
Not applicable
80
Guadalajara
2024-03-15
Active, closed
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603Type 2 Diabetes
DrugRetatrutide
Eli Lilly and Company
Phase 3
320
Chihuahua City, Guadalajara, Mérida, Veracruz
2024-03-15
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
100
Atizapán de Zaragoza, Guadalajara, Mérida, México, Monterrey
2024-03-14
By invitation
Effect of Consuming a Nutraceutical Composition on Signs and Symptoms in Adult Patients With Irritable Bowel Syndrome
NCT07103772Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome With Constipation, Irritable Bowel Syndrome Mixed
Universidad Autonoma de Nuevo Leon
Not applicable
94
Monterrey
2024-03-14
Active, closed
Psilocybin for Major Depressive Disorder (MDD)
NCT06308653Depressive Disorder, Major
DrugsPsilocybine·Psilocybin
Usona Institute
Phase 3
238
2024-03-13
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
Chihuahua City, Cuautitlán Izcalli, Jalisco, Mexico City, Morelos, Nuevo León, Yucatán
2024-03-13
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414Oligometastatic Prostate Cancer (OMPC)
DrugsPiflufolastat·Pluvicto
Novartis Pharmaceuticals
Phase 3
450
Mexico City, Huxquilucan
2024-03-12
Recruiting
Effects of Multiple-Session Transcranial Direct Current Stimulation (tDCS) on Behavioral, Physiological, and Electrophysiological Measures With Adults With Autism Spectrum Disorder (ASD)
NCT06495684Autism Spectrum Disorder, Autism or Autistic Traits
University of New Mexico
Not applicable
20
2024-03-12
Active, closed
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
NCT06348199Non-small Cell Lung Cancer Stage IV
DrugsKeytruda·Pembrolizumab
Samsung Bioepis Co., Ltd.
Phase 3
555
Aguascalientes, Guadalajara, Mexico City
2024-03-12
Recruiting
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT05659381Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer
DrugCisplatin
GOG Foundation
Phase 3
220
2024-03-08
Active, closed
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06402331Metastatic Castration-resistant Prostate Cancer
DrugFPI-2265
Fusion Pharmaceuticals Inc.
Phase 2
110
2024-03-05
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
17,300
Aguascalientes, Chihuahua City, Cuernavaca, Culiacán, Durango, Guadalajara, Hermosillo, León
2024-03-05
Recruiting
Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis
NCT06206083Endometrial Cancer
National Institute of Cancerología
Observational
64
Mexico City
2024-03-01
Active, closed
Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients
NCT07430683Cytomegalovirus Infections
University of Guadalajara
Phase 4
68
Guadalajara
2024-03-01
Active, closed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118Dermatitis Atopic
DrugsPimecrolimus·Amlitelimab·Tacrolimus
Sanofi
Phase 3
464
Monterrey, Veracruz
2024-02-29
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081Early Breast Cancer
DrugsLeuprolide·Goserelin·Exemestane·Ribociclib
Novartis Pharmaceuticals
Phase 3
1,400
Alc Cuahutemoc, Tlalpan, Monterrey
2024-02-28
Recruiting
EMUs: Enhanced Monitoring Using Sensors After Surgery
NCT06565559Surgery, Inpatients
University of Edinburgh
Observational
1,332
Veracruz
2024-02-28
Recruiting
The INVADE Study: INnominate Vein Approach for Central Catheterization in Difficult to cannulatE Patients
NCT04265703Critical Illness
Hospital Civil de Guadalajara
Not applicable
315
Guadalajara
2024-02-27
Recruiting
The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry
NCT06030063Cesarean Delivery, General Anesthesia
Yale University
Observational
5,000
2024-02-22
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966COPD (Chronic Obstructive Pulmonary Disease)
AstraZeneca
Phase 3
5,000
Benito Juárez, Chihuahua City, Cuernavaca, Culiacán, Guadalajara, Juriquilla, Metepec, Mexico City
2024-02-21
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311HIV, HIV Infections
DrugsBictegravir·Emtricitabine·Dolutegravir·Tenofovir alafenamide
ViiV Healthcare
Phase 3
307
Mérida
2024-02-21
Active, closed
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722Diabetes Mellitus, Type 2
DrugsRetatrutide·Semaglutide
Eli Lilly and Company
Phase 3
1,250
Guadalajara, Mexico City, Cuernavaca, Monterrey, Chihuahua City, Veracruz
2024-02-21
Recruiting
A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
NCT06006559Dengue
Novartis Pharmaceuticals
Phase 2
108
Oaxaca City, Veracruz
2024-02-20
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Cuauhtémoc, Mexico City, Puebla City, Toluca
2024-02-20
Active, closed
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
NCT05564403Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Recurrent Biliary Tract Carcinoma
DrugsLeucovorin Calcium·Binimetinib·5-FU·Fluorouracil
National Cancer Institute (NCI)
Phase 2
66
2024-02-09
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
DrugsZongertinib·Keytruda·Pemetrexed·Cisplatin
Boehringer Ingelheim
Phase 3
428
Mexico City, México, Veracruz
2024-02-09
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744Follicular Lymphoma (FL)
DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine
Genmab
Phase 3
1,095
2024-02-05
Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma
DrugsRelatlimab·Nivolumab
National Cancer Institute (NCI)
Phase 2/3
992
2024-02-02
Active, closed
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
DrugAdagrasib
Mirati Therapeutics Inc.
Phase 2
200
Colonia Nápoles, Colonia Roma, Toluca
2024-02-01
Active, closed
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
NCT06116890Neovascular Age-Related Macular Degeneration (nAMD)
DrugsKHK4951·Aflibercept
Kyowa Kirin Co., Ltd.
Phase 2
180
2024-01-31
Recruiting
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
NCT06003387Hemophilia B
CSL Behring
Phase 3
35
Mexico City
2024-01-30
Active, closed
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT05458674Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
DrugsTucatinib·Herceptin·Eribulin·Trastuzumab
Criterium, Inc.
Phase 2
17
2024-01-30
Active, closed
Registry of the Patient Experience for Carpal Tunnel Release
NCT06071468Carpal Tunnel Syndrome, CTS
Sonex Health, Inc.
Observational
1,424
2024-01-26
Active, closed
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150Multiple Myeloma
DrugsElotuzumab·Velcade·Talquetamab·Teclistamab
Janssen Research & Development, LLC
Phase 3
838
Guadalajara, Huixquilucan, Monterrey
2024-01-22
Active, closed
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
NCT06163326Vitiligo
DrugRitlecitinib
Pfizer
Phase 3
394
Mexico City, Monterrey, Veracruz
2024-01-19
Rows per page Showing 601–700 of 1579
Previous 5 6 7 8 9 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Mexican investigative site. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-mexico?page=7

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Mexico and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,579 studies in total at the last sync on 26 Sep 2026, 19:45 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in Mexico?

711 of the 1,579 studies in this register are recruiting new participants as of the 26 Sep 2026, 19:45 UTC sync. A further 64 have not yet opened recruitment, 742 are active but closed to new participants, and 62 are enrolling by invitation only. Eligibility for any study is decided by its study team.

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Breast Cancer (37) Obesity (27) Systemic Lupus Erythematosus (21) Non-Small Cell Lung Cancer (15) Prostate Cancer (15) Carcinoma, Non-Small-Cell Lung (15) Non-small Cell Lung Cancer (14) Asthma (14) Overweight (12) Acute Myeloid Leukemia (12) Multiple Myeloma (12) Ovarian Cancer (11) Malignant Solid Neoplasm (10) Type 2 Diabetes (10) Chronic Kidney Disease (10)
→

Browse trials by site location

Mexico City (586) Monterrey (370) Guadalajara (342) Chihuahua City (175) Mérida (135) Oaxaca City (122) México (99) Veracruz (92) Culiacán (85) León (85) Aguascalientes (84) Cuernavaca (70) San Luis Potosí City (69) Zapopan (51) Puebla City (50)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.